HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Enochian Biosciences (ENOB) Investors With Significant Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations
SAN FRANCISCO, June 7, 2022 /PRNewswire/ -- Hagens Berman urges Enochian Biosciences, Inc. (NASDAQ: ENOB) investors with significant losses to submit your transactions now.
Visit: www.hbsslaw.com/investor-fraud/ENOB
Contact An Attorney Now: [email protected]
844-916-0895
The investigation focuses on: (i) the accuracy of Enochian's pipeline of purported "miracle" disease treatments; and (ii) the adequacy of the Company's disclosures concerning its "scientific founder," "inventor" and largest shareholder, Serhat Gumrukcu – an individual who Enochian admits the Company is highly dependent upon.
Specifically, on May 25, 2022, federal authorities arrested Gumrukcu and another man for their alleged involvement in a "murder-for-hire" conspiracy, which resulted in the death of Vermont resident Gregory Davis. According to prosecutors, the murder was motivated by Davis' threat to inform the FBI that Gumrukcu had defrauded Davis in a multi-million-dollar oil deal.
Then, on June 1, 2022, Hindenburg Research published a scathing report on the Company. Hindenburg observed that Gumrukcu has an extensive criminal past that Enochian's Board and C-Suite have known about for years. Hindenburg also revealed Gumrukcu fabricated his credentials, engaged in the unauthorized practice of medicine, and siphoned $20 million from Enochian shareholders. Hindenburg also reported that a former executive left the Company after he concluded Gumrukcu lied about his work on Enochian's HIV project, lost scientific trust in Enochian's projects, and was fed up with Enochian's "culture of secrecy" discouraging management from questioning "financial movements" and Gumrukcu's credentials.
"We're focused on investors' losses and whether Enochian misrepresented Gumrukcu's background, accomplishments, and its need for him to achieve any semblance of commercial success," said Reed Kathrein, the Hagens Berman partner leading the investigation.
If you invested in Enochian and suffered substantial losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.
Whistleblowers: Persons with non-public information regarding Enochian should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Contact:
Reed Kathrein, 844-916-0895
SOURCE Hagens Berman Sobol Shapiro LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article